Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03029650 · ClinicalTrials.gov registry record · Phase 4
Scopolamine Patch Pharmacokinetics in Healthy Adults
A Phase 4 study, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT03029650 is a Phase 4 study that has completed, run by University of Iowa. The registered enrollment target is 26 participants.
The verdict
NCT03029650, a Phase 4 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The study to be performed will utilize already FDA-approved marketed products in healthy adults for the purpose to generate data for establishing rate of drug delivery of Transderm Scop® TDDS (transdermal drug delivery system) in healthy adults and to ensure safety of individuals utilizing these types of products.
Interventions
- DRUG Transderm Scop®
- DRUG Intravenous scopolamine hydrobromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03029650
The ClinicalTrials.gov registry entry for NCT03029650 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Transderm Scop® is the first listed.
NCT03029650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03029650 about?
NCT03029650 is a clinical study titled "Scopolamine Patch Pharmacokinetics in Healthy Adults". The study to be performed will utilize already FDA-approved marketed products in healthy adults for the purpose to generate data for establishing rate of drug delivery of Transderm Scop® TDDS (transdermal drug delivery system) in healthy adults and to ensure safety of individuals utilizing these typ...
What is the current status of trial NCT03029650?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2016-11. Estimated completion is 2018-03.
What interventions are being tested in trial NCT03029650?
The interventions under investigation include: Transderm Scop® (DRUG), Intravenous scopolamine hydrobromide (DRUG).
Who is sponsoring clinical trial NCT03029650?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.